Inactive Instrument

Idenix Pharmaceuticals Inc Share Price

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2015	AbbVie : Merck says hepatitis C drugs to lose breakthrough status	RE
2014	Apple : Wall St. edges up, lifted by mergers, acquisitions	RE

AbbVie : Merck says hepatitis C drugs to lose breakthrough status	04/02/15	RE
Apple : Wall St. edges up, lifted by mergers, acquisitions	10/06/14	RE
Apple : U.S. futures dip, S&P 500 comes off fourth straight record	10/06/14	RE
Bank of America : Dow, S&P 500 extend string of record closes; VIX up	09/06/14	RE
Bristol Myers Squibb Co. : Bristol to take $1.8 billion charge on hepatitis C drug failure	24/08/12	RE

Idenix Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Idenix Pharmaceuticals Inc.	10/06/14	PR
Idenix Pharmaceuticals : Clinical Test Results, Improved Medical Care, and Rejection of Buyout Proposal by Medical Companies - Analyst Notes on AstraZeneca, LifePoint, Insmed, Dendreon and Idenix Pharmaceuticals	23/05/14	PR
Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case	24/03/14	GL
Idenix Pharmaceuticals Inc : Files Patent Infringement Lawsuits Against Gilead Sciences in Europe	14/03/14	GL
Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Patent Interference	29/01/14	GL

Idenix Pharmaceuticals : Merck dépasse les attentes malgré la concurrence des génériques	29/07/14
Wall Street, dopée aux M&A, finit encore en hausse	09/06/14
Dow Jones Industrial Average : Wall Street finit encore en hausse	09/06/14
Gilead Sciences : Merck & Co acquiert Idenix Pharma pour 3,85 milliards de dollars	09/06/14
Apple : Les valeurs à suivre sur les marchés américains	09/06/14

Managers	Title	Age	Since
Teresa Dahlman IRC	Investor Relations Contact	-	-
Michele Liuzzi PRN	Corporate Officer/Principal	-	-
Adel Moussa PRN	Corporate Officer/Principal	-	28/02/02

Sector

	1st Jan change	Capi.
CSL LIMITED	-3.45%	87.17B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.1B
BIOGEN INC.	-16.98%	31.38B
UCB	+57.86%	25.12B
BIOMARIN PHARMACEUTICAL INC.	-16.24%	15.59B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	12B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.8B
INCYTE CORPORATION	-17.10%	11.8B
SWEDISH ORPHAN BIOVITRUM AB	+6.89%	8.81B